* EntreMed Inc., of Rockville, Md., licensed worldwide rights to 2-Methoxyestradiol (2-ME), an inhibitor of breast cancer and angiogenesis. A natural estrogen metabolite, 2-ME was discovered by Dr. Robert D'Amato and colleagues at Children's Hospital in Boston.

* Hybridon Inc., of Worcester, Mass., received approval to begin a Phase I/II clinical trial at the Bichat-Claude Bernard Hospital in Paris on its advanced chemistry antisense drug, GEM 132, to treat systemic cytomegalovirus (CMV) infection. CMV afflicts about 40 percent of late-stage AIDS patients, and often is associated with organ and bone marrow transplants.

* ICOS Corp., of Seattle, began a Phase II clinical trial of its Hu23F2G drug in multiple sclerosis patients experiencing acute exacerbations. A Phase II trial initiated in March 1996 involved use of Hu23F2G in patients with trauma-induced hemorrhagic shock. ICOS expects to begin another Phase II trial of the drug in myocardial infarction later this year.

* MacroChem Corp., of Lexington, Mass., received FDA clearance to begin Phase I/II clinical studies of its SEPA/testosterone gel for the transdermal delivery of testosterone without use of a patch. MacroChem's formulation combines testosterone with SEPA, its absorption enhancer for transdermal drug delivery.

* Medarex Inc., of Annandale, N.J., formed a strategic alliance with Utrecht University, of Utrecht, the Netherlands, involving research toward new therapeutic products for cancer, autoimmune disorders and infectious diseases. The research will be conducted by a Utrecht University research team led by J.G.J. van de Winkel, an expert in the biology of human Fc receptors, which is also the focus of Medarex's core technology. Van de Winkel will serve as scientific director of Medarex Europe BV, a new subsidiary of Medarex located in Utrecht. Medarex Europe will provide $500,000 in funding per year for the research projects and will receive rights to all technology and products developed.

* Oncor Inc., of Gaithersburg, Md., has concluded a private placement of $10 million in six percent, five-year unsecured notes convertible into shares of common stock, along with warrants to purchase 250,000 shares at $5 per share. The placement was completed with investment funds advised by Promethean Investment Group, LLC, of New York.

* Repligen Corp., of Needham, Mass., was awarded a $94,000 grant from the National Cancer Institute for the discovery of small molecule inhibitors of angiogenesis. The Phase 1 Small Business Innovation Research grant will fund synthesis of a library of 50,000 discrete compounds with Repligen's high-speed chemistry. The compounds will be screened with Repligen's high-throughput assays to detect potential inhibitors of the fibroblast and vascular endothelial growth factors believed responsible for angiogenesis.

* SuperGen Inc., of Emeryville, Calif., acquired rights to Immunex Corp.'s generic version of the anti-cancer drug etoposide. The product acquisition includes an undisclosed, up-front cash payment to Immunex, of Seattle, and involves rights to and inventory of its finished form of the drug, which was cleared by the FDA last year for treatment of small cell lung cancer and refractory testicular cancer.

* Triangle Pharmaceuticals Inc., of Durham, N.C., said preliminary clinical data on its MKC-442 anti-HIV drug showed it produced a significant reduction in the amount of HIV in the blood. Early data from the study will be presented at the Fourth Conference on Retroviruses and Opportunistic Infections in Washington.